Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
Securities code: 605116 Securities abbreviation: Oruit Announcement number: 2026-043 Bond code: 111021 Bond abbreviation: Orui convertible bonds
Orient Pharmaceutical Co., Ltd.
Announcement on the company’s products being selected for the twelfth batch of national centralized drug procurement
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
On July 31, 2026, Orient Pharmaceutical Co., Ltd. (hereinafter referred to as "Orient" or the "Company") participated in the twelfth batch of national drug centralized procurement bidding organized by the National Drug Joint Procurement Office (referred to as the "Joint Procurement Office"). According to the "Selection Result Table for the 12th Batch of Nationally Organized Drug Concentrated Procurement in Volume (GY-YD2026-1)" released by the Joint Procurement Office, the company's enzalutamide tablets and dydrogesterone tablets are planned to be selected in the twelfth batch of centralized bulk purchase. The relevant information is now announced as follows:
1. Basic information about the product to be selected
Specifications
Variety name Proposed product Indications
Suitable for "adult patients with metastatic hormone-sensitive prostate cancer (mHSPC); oral non-transformed enzalutamide for adult patients with metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of metastasis. Enzalutamide Tablets 40mg
Sudden-release dosage form; treatment of adult patients with metastatic castration-resistant prostate cancer (CRPC) who have failed androgen deprivation therapy (ADT) and are asymptomatic or minimally symptomatic and not receiving chemotherapy." It can be used to treat diseases caused by insufficient endogenous progesterone, such as dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles, dysfunctional uterine bleeding, and premenstrual Dydrogesterone Tablets 10mg
Sustained release dosage form syndrome, threatened abortion or habitual abortion caused by progesterone deficiency, infertility caused by luteal deficiency. Luteal support in assisted reproductive technologies.
Note: 1. The above are the proposed selection results. The final selection results and related selection information shall be subject to the notice issued by the Joint Procurement Office.
- According to relevant regulations, the procurement cycle of the products to be selected this time will be from the date of execution of the winning results to December 31, 2029.
2. Other relevant information about the products to be selected this time
- Enzalutamide tablets
In March 2026, the company received the "Drug Registration Certificate" for enzalutamide tablets approved and issued by the State Food and Drug Administration. For details, please refer to the "Announcement of Orient Pharmaceutical Co., Ltd. on the Company's Obtaining Drug Registration Approval" disclosed on the website of the Shanghai Stock Exchange on March 17, 2026 (Announcement No.: 2026-006). As of the end of the first quarter of 2026, this product has no sales.
- Dydrogesterone tablets
In June 2023, the company received the "Drug Registration Certificate" for Dydrogesterone Tablets approved and issued by the State Food and Drug Administration. For details, please refer to the "Announcement of Orient Pharmaceutical Co., Ltd. on the Company's Obtaining the Drug Registration Approval" disclosed by the company on the website of the Shanghai Stock Exchange on June 27, 2023 (Announcement No.: 2023-032). In 2025, the company's sales of this product in the domestic market will be approximately 184.3349 million yuan, accounting for 10.86% of the 2025 operating income.
3. The impact of this proposed election on the company
This centralized drug procurement is the twelfth batch of national drug centralized procurement organized by the state. In terms of implementation, medical institutions are required to give priority to the varieties selected in the centralized procurement and ensure that the agreed purchase volume is completed. If the company subsequently signs a purchase contract and implements it, it will help the above products quickly open up the domestic market, increase market share, enhance the company's brand influence, and have a positive impact on the company's future operations. However, the production and sales of products are easily affected by uncertain factors such as policies and market environment, and there is still uncertainty about the impact on future performance. Investors are kindly requested to make prudent decisions and pay attention to preventing investment risks.
Announcement is hereby made.
Board of Directors of Orient Pharmaceutical Co., Ltd.
August 4, 2026